Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets.
Le Cam-Duchez
Véronique
V
Frétigny
Mathilde
M
Cailleux
Nicole
N
Gandelin
Catherine
C
Lévesque
Hervé
H
Borg
Jeanne-Yvonne
JY
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000465:Algorithms; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D001777:Blood Coagulation / Q000187:drug effects* / Q000235:genetics; D065729:Cytochrome P-450 CYP2C9; D054796:Drug Dosage Calculations; D016903:Drug Monitoring; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D005602:France; D005838:Genotype; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000235:genetics*; D010597:Pharmacogenetics; D010641:Phenotype; D011110:Polymorphism, Genetic; D013927:Thrombosis / Q000097:blood / Q000517:prevention & control*; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage*; D055815:Young Adult
D005343:Fibrinolytic Agents; D014859:Warfarin; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; C578523:VKORC1 protein, human; D064417:Vitamin K Epoxide Reductases